Last Price$1.7(7.7%)
Market Cap$85.9M
LTM Goodwill & Intangible Assets
$0.0
YoY Growth
N/A
3Y CAGR
N/A
5Y CAGR
N/A
Stock quality & Intrinsic value
6/10
528.8% undervalued
Cabaletta Bio, Inc. Goodwill & Intangible Assets
Annual
Quarterly
LTM
Crunching data... Almost there!
| Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|---|
| Goodwill & Intangible Assets | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 |
Overvalued or undervalued?
Check the intrinsic value for CABA
and see if it's the right time to invest.
Cabaletta Bio, Inc. (CABA) Goodwill & Intangible Assets comparison analysis
General
LTM Goodwill & Intangible Assets
Growth
Company name
YoY growth
3Y CAGR
5Y CAGR
Cabaletta Bio, Inc.CABA
$0.0
N/A
N/A
N/A
Median Peer Set
$190.6M
(0.4%)
5.5%
0.0%
Novo Nordisk A/SNVO
$15.4B
72.0%
37.0%
80.3%
Vertex Pharmaceuticals IncorporatedVRTX
$1,913.9M
(0.7%)
10.9%
6.4%
BioNTech SEBNTX
$1,389.5M
27.4%
97.1%
67.6%
Regeneron Pharmaceuticals, Inc.REGN
$1,148.6M
10.6%
N/A
N/A
Incyte CorporationINCY
$269.4M
(3.5%)
(4.2%)
(5.1%)
United Therapeutics CorporationUTHR
$111.9M
(2.0%)
35.9%
(6.7%)
BeiGene, Ltd.BGNE
$53.9M
0.5%
56.0%
53.7%
Summit Therapeutics Inc.SMMT
$1,864.0K
(1.5%)
(46.8%)
(26.8%)
Alnylam Pharmaceuticals, Inc.ALNY
$0.0
(100.0%)
N/A
N/A
argenx SEARGX
N/A
N/A
N/A
N/A
CABA key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|---|
% growth | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% |
| Cost of Goods Sold (COGS) | 0.0 | 0.0 | 0.1 | 0.4 | 0.7 | 3.7 | 1.4 |
% margin | 0.0 0.0% | 0.0 0.0% | (0.1) 0.0% | (0.4) 0.0% | (0.7) 0.0% | (3.7) 0.0% | (1.4) 0.0% |
| Operating Expenses | 0.3 | 6.2 | 18.7 | 33.8 | 46.3 | 54.1 | 74.7 |
| Research & Development Expenses (R&D) | 0.0 | 4.5 | 11.7 | 21.4 | 32.5 | 39.3 | 55.4 |
| Selling, General & Administrative Expenses (SG&A) | 0.3 | 1.7 | 7.0 | 12.5 | 13.8 | 14.8 | 19.2 |
% margin | (0.3) 0.0% | (6.2) 0.0% | (18.7) 0.0% | (33.8) 0.0% | (46.3) 0.0% | (54.1) 0.0% | (74.7) 0.0% |
| Interest Income | 0.0 | 0.2 | 1.7 | 0.5 | 0.0 | 1.2 | 7.0 |
| Interest Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Pre-tax Income | (0.3) | (12.2) | (16.9) | (33.3) | (46.3) | (53.0) | (67.7) |
% effective tax rate | (0.3) 133.3% | (0.2) 1.9% | (1.8) 10.9% | (0.8) 2.5% | (0.8) 1.6% | (1.2) 2.2% | 0.0 0.0% |
% margin | (0.3) 0.0% | (12.2) 0.0% | (15.1) 0.0% | (32.5) 0.0% | (45.5) 0.0% | (51.8) 0.0% | (67.7) 0.0% |
| EPS | (0.01) | (0.84) | (0.63) | (1.40) | (1.77) | (1.77) | (1.65) |
| Diluted EPS | (0.01) | (0.84) | (0.63) | (1.40) | (1.77) | (1.77) | (1.65) |
% margin | 0.1 0.0% | (6.0) 0.0% | (18.7) 0.0% | (33.5) 0.0% | (45.6) 0.0% | (53.0) 0.0% | (73.2) 0.0% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Cabaletta Bio, Inc.'s Goodwill & Intangible Assets?
As of today, Cabaletta Bio, Inc.'s last 12-month Goodwill & Intangible Assets is $0.0, based on the financial report for Sep 30, 2024 (Q3’2024).
2) What is Cabaletta Bio, Inc.'s Goodwill & Intangible Assets growth rate?
Over the last year, Cabaletta Bio, Inc.'s Goodwill & Intangible Assets growth was N/A. The average annual Goodwill & Intangible Assets growth rates for Cabaletta Bio, Inc. have been N/A over the past three years, N/A over the past five years.